Ascentage Pharma Reports Positive Clinical Data for Three Cancer Therapies at ASCO 2026

summarizeSummary

Ascentage Pharma presented encouraging clinical data for its MDM2-p53 inhibitor alrizomadlin and updated results for olverembatinib in multiple cancer indications at the ASCO 2026 Annual Meeting.

check_boxKey Events

• Alrizomadlin (APG-115) in Pediatric Solid Tumors

  First dataset showed preliminary antitumor activity and manageable tolerability, including a complete response in pediatric rhabdomyosarcoma, and encouraging objective response rates in combination with lisaftoclax.

• Olverembatinib in CML-CP

  Updated data demonstrated deepening responses over time, with 91.3% complete cytogenetic response and 60.9% major molecular response at cycle 24, supporting its role as a second-line therapy.

• Olverembatinib + Blinatumomab in CML-LBP/Ph+ BCP-ALL

  First international data showed encouraging clinical activity with 91% complete response/incomplete hematologic recovery and high rates of minimal residual disease negativity in difficult-to-treat leukemias.

• ASCO 2026 Presentations

  The company presented six studies involving three key assets at the 62nd ASCO Annual Meeting, marking its ninth consecutive appearance at the prominent oncology conference.

auto_awesomeAnalysis

This filing details positive clinical trial results for three of Ascentage Pharma's key drug candidates, including first-in-human data for alrizomadlin in pediatric solid tumors with a complete response, and strong efficacy for olverembatinib in CML-CP and in combination with blinatumomab for difficult-to-treat leukemias. These results, presented at a major oncology conference, provide further validation for the company's pipeline and address significant unmet medical needs, potentially boosting investor confidence while the stock trades near its 52-week low.